Comprehensive immunohistochemical analysis of Her-2/neu oncoprotein overexpression in breast cancer: HercepTest (Dako) for manual testing and Her-2/neuTest 4B5 (Ventana) for Ventana BenchMark automatic staining system with correlation to results of (Q83239398)

From Wikidata

Jump to navigation Jump to search

scientific article published on 24 January 2009

Language	Label	Description	Also known as
English	Comprehensive immunohistochemical analysis of Her-2/neu oncoprotein overexpression in breast cancer: HercepTest (Dako) for manual testing and Her-2/neuTest 4B5 (Ventana) for Ventana BenchMark automatic staining system with correlation to results of	scientific article published on 24 January 2009

Statements

scholarly article

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19169706%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

Comprehensive immunohistochemical analysis of Her-2/neu oncoprotein overexpression in breast cancer: HercepTest (Dako) for manual testing and Her-2/neuTest 4B5 (Ventana) for Ventana BenchMark automatic staining system with correlation to results of fluorescence in situ hybridization (FISH) (English)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19169706%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

immunohistochemistry

1 reference

based on heuristic

inferred from title

author name string

Doris Mayr

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19169706%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

Sibylle Heim

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19169706%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

Cedric Werhan

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19169706%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

Evelyn Zeindl-Eberhart

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19169706%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

Thomas Kirchner

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19169706%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

publication date

24 January 2009

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19169706%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

Virchows Archiv

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19169706%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

454

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19169706%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19169706%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

241-248

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19169706%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

https://scigraph.springernature.com/pub.10.1007/s00428-009-0728-8

0 references

Evaluation of HER-2/neu gene amplification and overexpression: comparison of frequently used assay methods in a molecularly characterized cohort of breast cancer specimens.

1 reference

https://pubmed.ncbi.nlm.nih.gov/19169706

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prognostic importance of c-erbB-2 expression in breast cancer. International (Ludwig) Breast Cancer Study Group.

1 reference

https://pubmed.ncbi.nlm.nih.gov/19169706

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Overexpression of HER-2/neu is associated with poor survival in advanced epithelial ovarian cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/19169706

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

HER-2/neu and bcl-2 in ovarian carcinoma: clinicopathologic, immunohistochemical, and molecular study in patients with shorter and longer survival

1 reference

https://pubmed.ncbi.nlm.nih.gov/19169706

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Comparative methodological analysis of erbB-2/HER-2 gene dosage, chromosomal copy number and protein overexpression in breast carcinoma tissues for diagnostic use

1 reference

https://pubmed.ncbi.nlm.nih.gov/19169706

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Discrepancies in clinical laboratory testing of eligibility for trastuzumab therapy: apparent immunohistochemical false-positives do not get the message

1 reference

https://pubmed.ncbi.nlm.nih.gov/19169706

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/19169706

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

HER2 testing in the UK: consensus from a national consultation

1 reference

https://pubmed.ncbi.nlm.nih.gov/19169706

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Detection and quantitation of HER-2/neu gene amplification in human breast cancer archival material using fluorescence in situ hybridization

1 reference

https://pubmed.ncbi.nlm.nih.gov/19169706

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Quantitative justification of the change from 10% to 30% for human epidermal growth factor receptor 2 scoring in the American Society of Clinical Oncology/College of American Pathologists guidelines: tumor heterogeneity in breast cancer and its impl

1 reference

https://pubmed.ncbi.nlm.nih.gov/19169706

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

HER-2/neu assessment in breast cancer using the original FDA and new ASCO/CAP guideline recommendations: impact on selecting patients for herceptin therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/19169706

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Selecting Antibodies to Detect HER2 Overexpression by Immunohistochemistry in Invasive Mammary Carcinomas

1 reference

https://pubmed.ncbi.nlm.nih.gov/19169706

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Real-world performance of HER2 testing--National Surgical Adjuvant Breast and Bowel Project experience

1 reference

https://pubmed.ncbi.nlm.nih.gov/19169706

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Grading of ovarian carcinomas

1 reference

https://pubmed.ncbi.nlm.nih.gov/19169706

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

HER2 evaluation using the novel rabbit monoclonal antibody SP3 and CISH in tissue microarrays of invasive breast carcinomas

1 reference

https://pubmed.ncbi.nlm.nih.gov/19169706

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A new rabbit monoclonal antibody (4B5) for the immunohistochemical (IHC) determination of the HER2 status in breast cancer: comparison with CB11, fluorescence in situ hybridization (FISH), and interlaboratory reproducibility

1 reference

https://pubmed.ncbi.nlm.nih.gov/19169706

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Evaluation of HER-2/neu immunohistochemical assay sensitivity and scoring on formalin-fixed and paraffin-processed cell lines and breast tumors: a comparative study involving results from laboratories in 21 countries

1 reference

https://pubmed.ncbi.nlm.nih.gov/19169706

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Therapy of breast cancer with molecular targeting agents.

1 reference

https://pubmed.ncbi.nlm.nih.gov/19169706

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A formalin-fixed, paraffin-processed cell line standard for quality control of immunohistochemical assay of HER-2/neu expression in breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/19169706

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

HER-2/neu as a predictive marker of response to breast cancer therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/19169706

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Amplification and overexpression of HER-2/neu in carcinomas of the salivary gland: correlation with poor prognosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/19169706

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Low HER2/neu gene expression is associated with pathological response to concurrent paclitaxel and radiation therapy in locally advanced breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/19169706

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S00428-009-0728-8

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19169706%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19169706%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q83239398&oldid=2166088787"